NCT03292406 - A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

March 17, 2020

Study Completion Date

March 17, 2020

Conditions

Cutaneous T Cell Lymphoma

Interventions

DRUG

Placebo

Non active ingredients of CD11301

DRUG

CD11301 0.03%

Topical Gel

DRUG

CD11301 0.06%

Topical Gel

Trial Locations (21)

10117

Galderma Investigational Site, Berlin

15213

Galderma Investigational Site, Pittsburgh

19104

Galderma Investigational Site, Philadelphia

19107

Galderma Investigational Site, Philadelphia

24105

Galderma Investigational Site, Kiel

27710

Galderma Investigational Site, Durham

32429

Galderma Investigational Site, Minden

44093

Galderma Investigational Site, Nantes

47805

Galderma Investigational Site, Krefeld

48149

Galderma Investigational Site, Münster

60611

Galderma Investigational Site, Chicago

68167

Galderma Investigational Site, Mannheim

69310

Galderma Investigational Site, Pierre-Bénite

75010

Galderma Investigational Site, Paris

75231

Galderma Investigational Site, Dallas

77030

Galderma Investigational Site, Houston

92868

Galderma Investigational Site, Orange

94304

Galderma Investigational Site, Palo Alto

97080

Galderma Investigational Site, Würzburg

06032

Galderma Investigational Site, Farmington

02115

Galderma Investigational Site, Boston